| abstract |
The present invention relates to combinations for the treatment or prevention of non-Hodgkin's lymphoma (NHL) from a) a compound 2,3-dihydroimidazo [1,2-c] quinazoline, namely 2-amino-N- [7-methoxy-8- (3- morpholin-4-ylpropoxy) -2,3-dihydroimidazo [1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamide and b) one or more additional active agents selected from the group consisting of PI3Kδ-selective inhibitor GS-1101, BTK inhibitor Ibrutinib, IKK inhibitor BAY Compound B and Refamethinib (refametinib) (BAY 86-9766 (RDEA-119)), with non-Hodgkin's lymphoma (NHL) selected from relapse lim ohms or refractory lymphoma after first-line, second-line therapy, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), marginal lymphoma (LMF), diffuse B-cell lymphoma (DLVC) ), mantle cell lymphoma (MCL), transformed lymphoma (TL) or peripheral T-cell lymphoma (PTCL); a pharmaceutical composition for treating or preventing non-Hodgkin's lymphoma (NHL) containing a combination of a) the indicated compound and b) the said one or more additional active agents. |